Form 4 for MYGN MYRIAD GENETICS INC
Accepted 2026-06-12 18:05:58 ET · period of report 2026-06-11 · accession 0002065630-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-12 18:05 | 2026-06-11 | MYGN | Donnelly Brian J | Chief Commerical Off | A - Grant | $3.94 | +5,000 | 573.4K | +0.9% | +$19.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-11 | A | A | 5,000 | $3.94 | 573,363 | D | — | — | (F1) These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |